Related Experiment Video
Updated: May 3, 2026
10:56
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
7.5K
Predicting non-adherence in patients with familial hypercholesterolemia.
J M H Galema-Boers1, M J Lenzen, R T van Domburg
1Pharmacology, Vascular and Metabolic Diseases Section of the Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
European Journal of Clinical Pharmacology
|January 23, 2014
Summary
Non-adherence to statins in Familial Hypercholesterolemia (FH) is linked to younger age and cholesterol levels. A new model predicts non-adherence in FH patients, aiding in improved treatment outcomes.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Familial hypercholesterolemia (FH) is an autosomal dominant disorder significantly increasing the risk of premature coronary heart disease (CHD).
- Effective CHD prevention relies on lifestyle modifications and lifelong statin therapy, with adherence being crucial for risk reduction.
Purpose of the Study:
- To identify key determinants of non-adherence to statin treatment in patients with FH.
- To develop and validate a predictive model for identifying FH patients at risk of non-adherence.
Main Methods:
- A single-center survey was conducted among adult heterozygous FH patients receiving specialized care.
- Data collected included clinical information and patient-reported medication adherence via questionnaire.
Main Results:
- Of 321 FH patients, 89% reported high statin adherence (>90%).
- Non-adherence was significantly associated with younger age (OR=10.64), high on-treatment total cholesterol (OR=4.29), and low untreated total cholesterol (OR=3.94).
- A predictive model incorporating these factors demonstrated good performance (c-index=0.78).
Conclusions:
- A predictive model based on age and cholesterol levels can identify FH patients likely to be non-adherent to statins.
- This model represents a potential tool for improving statin adherence in this high-risk population.
- Further prospective research is needed to validate the model's clinical utility.
Related Concept Videos
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429